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Background: This study intends to evaluate the delays in the diagnostic pathways for
primary lung cancer in Southern Norway, and to compare results with recommendations
from the British Thoracic Society (BTS) and the Swedish Lung Cancer Group (SLCG).
Design: A questionnaire-based prospective study of all patients diagnosed with primary
lung cancer in Southern Norway from June14, 2002 to June 13, 2005.
Results: Half of the 479 patients were referred to a specialist in pulmonology within 3
weeks (median) of first seeing their doctor concerning symptoms of malignant pulmonary
disease. 71% of patients were seen by pulmonologist within 1 week of received referral,
and not 100% as proposed by the BTS. 52% of the patients were diagnosed and informed of
their disease within 2 weeks (BTS recommend 100%) of having received the referral letter,
and 68% within 3 weeks (SLCG recommend 80%). 62% started treatment within 1 month of
first contact with pulmonologist (SLCG 80%).
Conclusion: The delays in diagnosing lung cancer in the Agder region were within BTS and
Swedish recommendations in 52–71% of cases. Although our results show good standings
compared to other studies, the potential improvements for both the referring GP and the
specialist investigators are discussed.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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sand, Norway.Introduction
Primary lung cancer is the most important cause of cancer-
related mortality in the Western world today. The same
accounts for Norway, and the incidence is still increasing.
The Agder counties in Southern Norway have, for partially
unknown reasons, a higher incidence than Norway at large
(The Norwegian Cancer Registry, 2005). For example, the
incidence of primary lung cancer has almost doubled among
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H.B. Rolke et al.1252women in Eastern Agder from 1985 to 1995.1 Agder serves
260 000 inhabitants. Thus, about 170 new cases of primary
lung cancer are diagnosed in this area each year, where two
main hospitals treat persons with these conditions, i.e.
Sorlandet Sykehus Kristiansand (SSK) and Sorlandet Sykehus
Arendal (SSA), offering all regular kinds of tumour-reducing
treatments, including radiotherapy.
Although the overall prognosis for primary lung cancer
is poor, with a mean survival of less than a year, rapid
diagnosis and assessment are important to determine
operability, suitability for radiotherapy, chemotherapy or
palliative interventions, and to minimise the anxieties of
patients and their families. The British Thoracic Society
(BTS) and the Swedish Lung Cancer Group (SLCG) have
therefore made recommendations concerning time limits for
diagnosing lung cancer.2–4 Such recommendations are absent
in Norway.
We thus intended to evaluate whether our clinics keep
within the Swedish and the British time suggestions, and
reveal needs for improvement to reduce delays in the
diagnostic pathways. A Pub Med search for articles from
Western Europe and North America on delays in the
diagnostic process of lung cancer, shows that several studies
have assessed delays for patients undergoing surgery, but
studies are mostly retrospective.5–8 In a review article,
Jensen et al.9 comment that selection bias can be
considerable in studies on patients recruited from surgical
or oncological departments, as these never include patients
with known late-stage disease. During the last decade, only
two smaller studies by Koyi et al.10 (n ¼ 134) and Deegan et
al.11 (n ¼ 92) have prospectively examined the various
patient-, doctor- and hospital delays in the diagnosis and
treatment of all mainstream non-selected lung cancer
patients.Methods
All patients diagnosed with primary lung cancer in Southern
Norway, i.e. the Agder counties (Aust-Agder and Vest-
Agder), were included in this prospective study between
June 14, 2002 and June 13, 2005. After signing a written
informed consent, a questionnaire, especially made for the
study, concerning start of cancer-related symptoms and first
date of contacting their doctor about these symptoms, was
answered. For those patients who did not recall exact date
of first symptom or first contact with doctor, only as ‘‘the
beginning of’’, ‘‘the end of’’ or ‘‘the midst of month’’, this
was transformed into the 1st, the 30th or the 15th of the
actual month. If only the month was remembered, the
protocol stated to record it as the 15th. Patients answering
questionnaires from their home address were, in case of
delayed replies, repeatedly (at least twice) reminded by
telephone and/or mail. Physical status rating according to
Eastern Cooperative Oncology Group (ECOG) Performance
Status were noted for those who were too ill to answer these
questionnaires.12 If not able to sign the informed consent,
an allowance to use basic medical information from the
journal was attained by oral consent from patients or
relatives. Relatives were occasionally able to answer some
baseline questions concerning symptom start, doctor visits,
smoking, etc.Dated referral from general practitioner or other hospital
wards, as well as date of referral receipt in the clinic, were
collected as soon as possible after the first contact with the
lung department. All definitions of delays used in this article
were: Patient delay: Time from first symptom to first personal
contact with doctor. GP delay: Time from first contact with general practi-
tioner (GP) to date on written referral. Referral delay: Time from dated referral receipt to first
contact with pulmonary consultant. Specialist delay: Time from first contact with pulmonary
consultant to dated diagnostic histology/cytology. Informed diagnostic delay: Time from decision of doing a
diagnostic procedure to informing patient of diagnosis.
Time from decision was stated as the date of referral
receipt+2 days, which is considered the mean time used
(including weekends and public holidays) before a
decision of diagnostic procedure/sequence was done. Hospital delay: Time from first contact with pulmonary
consultant to start of treatment. Total delay: Time from first symptom to start of
treatment.
Patients presenting with metastases in other organs,
thereby being diagnosed before referred to a pulmonary
consultant, were excluded from statistical analyses on
delays, since our main goal was to investigate delays in
our common diagnostic pathways. If those had been
included in the analyses, diagnostic delays would have been
incorrectly shortened, thereby introducing a selection bias
for the main purpose of the study.
Medical information about histology and staging according
to C. Mountain’s revision in the International System for
staging of lung cancer (TNM-stage) of disease and treatment,13
were collected from the patients’ hospital records. Histology
was classified according to the revised WHO classification of
October 10, 1998.14,15 For those without histology, date of
clinical decision was chosen as diagnostic date.
Because the BTS recommendations2 principally concern
the process of patient care, most of them represent
considered clinical opinion, compatible with what evidence
there is, and are not recommendations based just upon
published scientific evidence.
The BTS recommendations of interest for our study state
that:K Patients referred by general practitioners, who have
obvious clinical evidence of lung cancer, should be seen
within 1 week of referral receipt in a respiratory
physician’s clinic, i.e. Referral delay.
Regarding the confirmation of the diagnosis:K The results of bronchoscopy or any other similar
diagnostic test, including the histological or cytological
result, should be available and communicated to the
patient within 2 weeks of a decision to do it, i.e.
Informed diagnostic delay.
The recommendations from the Swedish Lung
Cancer Study Group3 state that 80% of patients
with:
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before they are investigated by a specialist, i.e. Referral
delay.K diagnosed lung cancer should wait no more than 3 weeks
since first specialist investigation to a treatment decision
is made and no more than 10 days from a treatment
decision was made until start of treatment, summarised
as Hospital delay.
Our local standard at the start of the study was that
patients referred with a suspicion of lung cancer, should be
investigated within 2 weeks.
The two hospitals were compared to look for differences
in delays related to the diagnostic process. Age, gender and
hospital (SSA versus SSK) were chosen as explanatory
variables affecting delays in the multiple logistic regression
analyses. Further, the histological class, i.e. small cell lung
cancer (SCLC) versus non-small cell lung cancer (NSCLC),
was chosen since SCLC grow and disseminate earlier than
NSCLC, and thus give early symptoms. Myrdal et al.16 found
more pronounced interaction between short delay and poor
prognosis in patients with advanced tumour stage.
We also wanted to evaluate whether radiology before
referral to the chest clinic could influence the GP or
specialist delays. Main diagnostic procedure leading to the
diagnosis was noted and compared between the two
hospitals.
Statistical methods
Statistical descriptive analyses were performed with SPSS 13
(Statistical package for Social Sciences, SPSS Inc., Chicago,
USA). All days recorded include weekends and public
holidays. Continuous data were, when non-normally dis-
tributed, as judged by measures of dispersion (SD) and/or bar
charts, and, when in doubt, by Lilliefors’ test for skewed-
ness, analysed with non-parametric tests, such as Man-
n–Whitney U-test. Skewed data are shown with the median
value as a measure of central tendency and with the
interquartile range (IQR, i.e. 25th and 75th percentiles) as
the measure of dispersion. Normally distributed data were
evaluated with t-test. The corresponding central tendencyEligibl
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Evaluat
479
•
•
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Figure 1 Eligible, excluded, not inand dispersion values are displayed as mean and standard
deviation (SD), respectively. Proportions were analysed with
w2-tests. Extreme values, judged as definite outliers, were
extracted from analyses. Differences were considered
statistically significant with an alpha below 0.05 (Po0:05),
two-sided test. Data on delays also showed skewed
distribution. Hence, data were transformed into categorical
variables with a cut-off at 21 days for all delays, except
referral delay (cut-off at 7 days). Multiple logistic regression
analyses on delays were then run with backward stepwise
conditional methods, testing for the following categorical
variables: Age (cut-off: p70 years ¼ 0, 470 years ¼ 1),
gender (men ¼ 0, female ¼ 1), ECOG performance status
(status 0–2 ¼ 0 and 3–4 ¼ 1), TNM stage (stage 1a–3a ¼ 0
and 3b-4 ¼ 1), histology (NSCLC ¼ 0 and SCLC ¼ 1), clinic
(SSK ¼ 0 and SSA ¼ 1), and whether X-ray or CT scan of the
chest was required by referring doctor or not (radiology
before referral ¼ 0 and not ¼ 1).
Proportional differences between our results and BTS and
SLCG recommendations were tested through w2-tests in
Sample Power (Sample Power, SPSS Corp., Chicago, USA),
assuming a sample size of 470 patients and with a power of
above 90%, two sided test.Results
Of 492 eligible patients, 479 patients were successively
enrolled over a 3-year period, i.e. an inclusion rate of 97%
(see Fig. 1). 18% of patients were too ill to answer
questionnaires at the time of diagnosis, already being in
very poor condition by the time diagnosis was established
due to for example sequela after cerebral thrombus,
extreme fatigue or depression. It seems important to
include these patients in the study, as they represent the
sickest, often those with long pre-hospital delays, and
requiring either palliative radiotherapy or best supportive
care only.
Another 7.5% (n ¼ 36) were diagnosed at the time of
death or by autopsy. 75% of questionnaires regarding delays
were answered in the clinic, while the rest were answered
at home and mailed. The mean age was 67 for women and 68e
ed
9 not included
 no consent
 
moved out of the region
 
did not speak Norwegian
The inclusion rate was 97%.
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•
cluded and evaluated patients.
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Table 1 Baseline characteristics for primary lung
cancer in Agder counties, Southern Norway.
(n) Unless stated
differently
Age: yr, mean (SD) 68 (11)
Sex, females 42 (199)
Current smokers 47 (227)
Histology
SCLC 21 (102)
Adenocarcinoma 33 (157)
Squamous cell ca. 25 (113)
Large cell/undifferentiated 12 (59)
No histological diagnosis 10 (48)
TNM stage (Mountain)
Ia 8 (37)
Ib 8 (36)
IIa–IIb 4 (21)
IIIa 8 (40)
IIIb 23 (109)
IV 49 (235)
Performance status (ECOG)
0 14 (65)
1 33 (160)
2 8 (86)
3 22 (106)
4 11 (52)
N ¼ 479.
SCLC ¼ small cell lung cancer.
TNM ¼ tumour node metastasis staging of lung cancer,
according to Mountain’s revised classification.13 Stages IIIb
and IV are advanced cancer, not leaving chance of being
cured. Performance stage according to Eastern Cooperative
Oncology Group/World Health Organization.12
H.B. Rolke et al.1254for men. 95% had a positive smoking history (smokers and
ex-smokers), half of the patients still smoking (Table 1).
More than two-thirds (72%) of patients were in advanced,
non-operable stage of lung cancer and half of them had
distant metastases (stage IV) at the time of diag-
nosis. One in five was diagnosed with SCLC and seven in
ten with NSCLC.
Median and mean patient delays were approximately 3
weeks and 3 months, respectively, thereby revealing the
considerably skewed distribution of data (Table 2 and
Fig. 2).
Half of the patients contacted their doctor within 3 weeks
after their first cancer-related symptom. The general
practitioner delay was at large comparable to the patient
delay, being somewhat lower, though not statistically
significant, for the mean value (66 versus 79 days,
P ¼ 0:80). 88% were seen by a pulmonary consultant within
2 weeks of referral receipt (Fig. 3, Referral delay), the
median being 1 day (IQR: 0–7). Most of those who waited
longer, had either imprecise information or another diag-
nosis, without a suspicion of malignancy, in the referral
letter.71% of patients experienced a referral delay of less than 1
week, in comparison to the BTS recommendation proposing
all (100%) patients to be investigated within a week
(Po0:001, w2-test). The corresponding proportion in the
Swedish guidelines were 80% (P ¼ 0:05). Half of the patients
were diagnosed and informed within 2 weeks, according to
the British recommendations (52% vs. 100%, Po0:001), and
two-thirds within 3 weeks, as suggested by the Swedish
recommendations (68% vs. 80%, Po0:01). Patients were
informed 1 (median) day (IQR: 0–5) after dated histological/
cytological diagnosis. For patients receiving active, tumour-
reducing treatment (n ¼ 311), another 13 (median) days
(IQR: 4–23) passed before treatment was initiated. 62% of
these patients were diagnosed and had treatment started
within 31 days, not 80% as proposed by the Swedes
(Po0:01). Median total delay was just below 4 months.
3/4 of patients had chest X-ray performed before they
were referred to a pulmonary consultant. Although the GP
delay thereby seemed somewhat shortened in multivariate
analyses, an X-ray prior to referral to pulmonologist did not
affect the delay from GP to final diagnosis.
Advanced ECOG performance status and advanced TNM
stage reduced referral delay with statistical significance,
with a halved odds ratio (0.49 and 0.48 with a 95% CI
0.27–0.90 and 0.28–0.80, respectively). Advanced TNM
classification also reduced specialist-delay (OR 0.45, 95%
CI 0.25–0.79), informed diagnostic delay (OR 0.42, 95% CI
0.25–0.68) as well as hospital delay (OR 0.43, 95% CI
0.24–0.78).
Female gender (OR 0.51, 95% CI 0.29–0.91) was asso-
ciated with shorter specialist delay. SCLC also had a
definitely shorter hospital delay than NSCLC (OR 0.29, 95%
CI 0.16–0.53).
Specialist delay was longer at SSA (11, median, IQR 7–18)
than at SSK (8, 3–21), Po0:004. The corresponding values
for informed diagnostic delay were 17 (10–25) at SSA versus
12 (5–25) at SSK, Po0:002. Time from receiving diagnosis to
informing the patient was 1 day (median, IQR 0–4) at SSK
compared to 3 (0–7) at SSA, Po0:0001.Discussion
71% of patients with a suspicion of primary lung cancer
experienced a ‘‘Referral delay’’ of less than 1 week in the
Agder region, Norway, while the BTS and Swedish recom-
mendations propose 100% or 80% of patients, respectively, to
be within suggested time limits. The corresponding propor-
tions for ‘‘Informed diagnostic delay’’ were 52% within 2
weeks and 68% within 3 weeks, respectively. 62% of patients
experienced a ‘‘Hospital delay’’ of less than 31 days. We
thus, in comparison with international recommendations,
uncover a considerable potential for improvement in the
diagnostic pathways of lung cancer in this region.
A shortcoming of our study might be that only 75%
answered the baseline questionnaires themselves. Hence,
when patients were not able to answer the questions
themselves, efforts were made in collecting detailed
information from relatives. Nevertheless, some uncertainty
and selection bias might have been introduced here.
However, another comparable, although retrospective,
study did not include patients who were offered best
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Figure 3 Delays in the diagnosis of primary pulmonary carcinoma within 1, 2 and 3 weeks.
Table 2 Delays in the diagnostic pathway for primary lung cancer in Southern Norway.
N Days o3 weeks (%) BTS recommendations Swedish recommendations
Median (IQR) Mean (SD)
Patient delay 376 19 (2–77) 79 (179) 51
GP delay 404 22 (4–61) 66 (143) 50
Referral delay 463 1 (0–7) 6 (17) 95 Within 1 week 71% within 1 week 71%
Specialist delay 448 8 (3–19) 17 (30) 82
Informed diagnostic delay 441 14 (6–25) 25 (37) 68 Within 2 weeks 52% Within 3 weeks 68%
Hospital delay 310 25 (13–42) 35 (36) 44 Within 31 days 62%
Total delay 273 118 (68–220) 219 (313) 2
N ¼ 479.
Definitions: see text.
The Swedish recommendations3 recommend 80% of patients to experience a
 referral delay within 7 days
 hospital delay within 31 days
The BTS recommendations2 advice
 referral delay no more than 1 week
 information to the patient about histology/cytology should be within 2 weeks of the decision to do the diagnostic procedure
118
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Figure 2 Delays (median) in the diagnostic process of primary pulmonary carcinoma, Southern Norway, 2002–2005.
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H.B. Rolke et al.1256supportive care only.16 By also including those patients who
were offered only best supportive care, thereby to a larger
extent those with an advanced disease stage and low
performance status as well as more elderly persons, data
will involuntary be more imperfect. Since most patients had
a smoking history and thereby many patients already
suffered from COPD or cardiovascular disease, with cough
and dyspnoea as common symptoms, one could argue that
this might influence both the patient and referral delays.
However, we have no data available to investigate these
interactions more thoroughly.
Salomaa et al.17 also included those offered best
supportive care (132 patients). Both ‘‘Patient (14 days,
median) and GP delay’’ (16 days) seemed slightly shorter in
Salomaa’s study, compared to our study (19 and 22 days,
respectively), while ‘‘Specialist delay’’ in our study seemed
shorter (8 versus 15 days). Specialist delay is of course of
greatest importance in our study, since it reveals our clinical
results directly. Thus, although our results may not fulfil BTS
and Swedish recommendations, they seem somewhat better
than the only comparable study from Finland regarding
specialist handling. We thus believe that we, considering the
non-selected patient population, both present results with a
sound validity and also relatively good values.
In our opinion, the Swedish recommendations, where 80%
of patients should experience to be within the suggested
time limits, seem more realistic than the British. Regarding
‘‘Referral delay’’ we have results close to the Swedish
recommendations. We believe ‘‘Referral delay’’ could be
shortened if referring physicians are encouraged to make
telephone calls or telefax referrals instead of writing letters
of referral. This delay could of course also be shortened if
some referring physicians improve their information with a
clearer suspicion of lung cancer in their referring letters.
‘‘Informed diagnostic delay’’ could also be shortened by
several manoeuvres. First, it will be looked at whether
changes in first choice of diagnostic procedures could
establish the diagnosis more quickly. Second, the time to
first diagnostic procedure might also be shortened if given
higher priority and converted to improved hospital logistics.
Third, the delay from established morphological diagnosis to
informing patients could probably also be shortened by
approximately 1 day, although many specialists would
consider our delay of 2 days already to be very efficient
indeed.
For ‘‘Specialist delay’’ the median time from first
investigation at hospital to established histological diagnosis
was 8 days, the mean being 17 days. Thus, the diagnostic
process lasts too long for some patients. Multidisciplinary
team meetings are held once a week. Possible diagnostic
procedures are discussed if assistance from radiologist or
surgeon is considered necessary. Otherwise, treatment is
discussed after histological diagnosis is established. Some
times this is discussed after the patient has been informed,
at other times before-, depending on whether line of
treatment seems debatable.
More than two-thirds of patients were already in
advanced tumour stage at time of diagnosis (stages IIIb
and IV). This is a higher proportion than in most other
studies. This could have several reasons. First, since this
study included all patients, not only those receiving tumour
reducing treatments, more advanced cancers would natu-rally be included, giving higher proportions of patients with
advanced cancer. Second, the diagnostic standards were
adequate and updated, thereby resulting in a higher
precision in TNM classification than in most previous studies.
Third, there was a relatively high proportion of females in
the studied population, as already known from previous data
from the Norwegian Cancer Registry. But whether this should
partly explain a high proportion of advanced cancer stages,
we are not able to answer. Fourth, as many of these patients
have serious comorbidity, such as COPD, they seem to
tolerate a large extent of symptoms before they or their GP
realise that there is need for further investigations. The
advanced stage is partly why many were too ill to answer
questionnaires, being weakened by fatigue or nausea.
Interestingly, whether X-ray or CT scan of the chest were
done before referral to specialist or not, did not influence
the total time to diagnosis.
The multivariate logistic regression analysis showed that
especially patients with advanced tumour stage, but also
poor performance status, had a higher probability of a short
referral delay. One might expect these patients to have
waited longer before contacting their GP, thus presenting
with a heavy symptom load. However, a longer ‘‘Patient
delay’’ was not evident for these patients compared to those
with less advanced disease. An explanation could be the
multi-morbidity for many of those patients, with for
example previous experiences of daily cough, sputum and
recurrent lower airway infections. We have no information
to what extent patients supersede symptoms in this survey.
An advanced TNM classification was also associated with
shorter ‘‘Specialist, Informed diagnostic and Hospital de-
lays’’. This is most probably due to more easily accessible
tumour masses for biopsy in advanced disease, and a greater
need for rapid, symptom-related treatment than in less
advanced disease.
SCLC is associated with a shorter time from established
diagnosis to start of treatment (i.e. reduced ‘‘hospital
delay’’, but not ‘‘Specialist delay’’ or ‘‘Informed diagnostic
delay’’), compared to NSCLC. This is most probably due to
the rapid onset chemotherapy for a high proportion of
patients with SCLC. Persons with NSCLC are to a much larger
extent referred to surgery or radiation as first line
treatment, thereby including administrative delays not
experienced with our in-department chemotherapy.
The basis for this study was to find areas for enhancement
in the diagnostic procedure. The results revealed important
shortcomings and a basis for improvement. In this process, a
comparison of the two hospitals also revealed differences in
the diagnostic logistics of local interest, giving both
hospitals ideas on how to increase the efficiency of the
diagnostic processes. Both hospitals have after the study
changed routines to improve their standards, e.g. such as
handling referrals more efficiently. We thus believe that
similar registrations profitably could be introduced in other
hospitals to reveal shortcomings and improve standards.Acknowledgements
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